Tech
Sichuan Kelun-Biotech Biopharmaceutical announced the positive first-in-human study results for its novel B7-H3 ADC SKB500 at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, United States. Professor Liu Haifeng from Jilin Provincial…
Impact: Sichuan Kelun-Biotech Biopharmaceutical is a holding subsidiary of Sichuan Kelun Pharmaceutical, meaning the positive study results for SKB500 will also positively impact Sichuan Kelun Pharmaceutical's market standing.
Jun 03, 2026 · 6 articles